3 funding opportunities are listed in this category
National Academy of Engineering Fritz J. and Dolores H. Russ Prize
The Fritz J. and Dolores H. Russ Prize, established in October 1999, is named after Fritz Russ, an esteemed engineer and founder of Systems Research Laboratories, and his wife Dolores Russ, a long-time supporter and benefactor of the engineering industry.The NAE established the prize at the request of Ohio University to honor the Russes for their dedication to education and the field of engineering. Fritz Russ graduated from Ohio University in 1942 with a B.S. in electrical engineering.The Russ Prize recognizes an outstanding achievement in bioengineering that improves the human condition. This achievement should help the public better understand and appreciate the contributions of engineers to our health, well-being and quality of life. An auxiliary purpose of the Russ Prize is to encourage collaboration between the engineering and medical/biological professions to work closely together.Awarded biennially (odd number years), the recipient receives a $500,000 cash award and a gold medallion. NAE members and non-members worldwide are eligible to receive the Russ Prize.
The Russ Prize will recognize achievements in bioengineering in its initial years.Examples of bioengineering include research, education, or product development in such areas as biomedical instrumentation, separation, and control systems; aerospace biomedical engineering; diagnostic technologies; applied genetic engineering; pharmaceutical processing; prosthetic technologies; biomolecular engineering; medical engineering; and applied physiological systems.The Russ Prize is awarded for a specific achievement or for a series of achievements in bioengineering, and may be awarded to an individual or a group of individuals contributing to the same achievement(s). The Russ Prize is not awarded posthumously. Recipients of the Charles Stark Draper Prize are not eligible for the Russ Prize. NAE members and non-members world-wide are eligible to receive the Russ Prize.
Russ Prize Selection CriteriaThe narrative description of the achievement that accompanies the nomination form and additional materials should provide qualitative and quantitative evidence that the following criteria are met: * Demonstrated success in the number of people actually or potentially benefited by the innovation or achievement, and the extent of this benefit. * Demonstrated novelty, originality, and fundamental character of the technical idea or concept underlying the innovation or achievement. * Demonstration that the innovation or achievement has removed fundamental barriers or constraints to subsequent incremental improvement and refinement, or that it embodies wholly new scientific principles. * Demonstrated richness of technical ramifications of the new concept or invention, and its applicability in many different areas of application far removed from each other. * Demonstrated follow- through on the part of the originating individual or team. Excellence in design, execution and management of the innovation, and commercialization or “operationalization ” of a new idea should be demonstrated, in addition to the ingenuity and novelty of the original technical conception of “proof of principle.” * Demonstrated economic impact, actual or potential, of the innovation or achievement. Economic impact would include gross revenues generated by a new product or process, cost savings made possible by a new process, reductions in environmental impact, or benefits to health and safety in the workplace or of consumers. * The achievement nominated helps increase the public understanding of the contributions and achievements engineers make to improve the human condition. * The award of the prize to the nominated achievement will provide encouragement for the engineering and medical/biological disciplines to more closely work together.A nomination form must be completed and submitted during the NAE Call for Nominations period starting January 4, 2010 ending April 1, 2010.
NAE AwardsNational Academy of Engineering500 Fifth Street, NW, Keck 1048Washington, DC 20001FaxAttn: NAE Awards(202) 334-2290
Targeted RFP – Biomedical Research: Establishment of a Research Consortium to Explore the Barriers to and Potential for Eradication of HIV Infection
Application Deadline: March 25, 2010 Available Support amfAR, The Foundation for AIDS Research, is pleased to announce plans to establish and support a consortium—consisting of several collaborations—of biomedical researchers to explore the barriers to and potential for eradicating HIV infection. Funding will be available for: Collaborations—Each collaboration is funded for a total of up to $300,000 for direct costs plus up to 20 percent for indirect costs. The performance period for collaborations funded under this RFP will be for one year starting May 1, 2010, and may be renewable for subsequent years. Each collaboration must consist of at least two interrelated research projects and involve at least two independent, faculty-level researchers. Background and Areas of Interest amfAR's research program is driven by the Foundation's mission to end the global AIDS epidemic through innovative research. amfAR plays a uniquely important role in AIDS research, identifying critical gaps in our knowledge of HIV and AIDS and supporting groundbreaking studies that often lack the preliminary data required by more traditional funders. The Foundation's research program focuses on efforts to prevent HIV infection among vulnerable populations and to improve treatment, with the ultimate goal of eradicating the virus in people living with HIV infection. This RFP solicits proposals for collaborations to explore the obstacles to and strategies for eradicating HIV infection. Highly active antiretroviral therapy (HAART) has significantly improved the health of individuals infected with HIV-1. However, if therapy is interrupted, there is a rapid resumption of viral replication. Understanding the mechanisms by which the virus is able to persist in the face of therapy is necessary in order to identify strategies that may interrupt viral persistence and ultimately lead to viral eradication. amfAR wishes to establish a consortium consisting of several collaborations. The purpose of the consortium is to explore barriers to and the potential for the eradication of HIV infection as a condition requiring medical treatment, i.e., a sterilizing or functional cure. amfAR would like to fund one collaboration in each of the following three areas. Some, but not all, potential topics of interest within each of the three collaboration areas are listed: Sterilizing cure: i.e., eliminating HIV from the body of an infected person Gene therapy techniques/vectors "Shock and kill” strategies Methods to identify and specifically target infected cells Replication and/or exploration of factors contributing to the Berlin patient outcome Functional cure: i.e., achieving a state of persistent HIV infection without the need for medical treatment What can be learned from specific populations of interest such as elite controllers, long-term non-progressors, and patients who initiate therapy during acute infection? How can this information be applied to devising a functional cure? What are the immune or other implications of persistent infection, even in the absence of disease? Characterizing viral reservoirs: Which cells under which conditions contribute which roles to the reservoir(s)? Mechanisms for reservoir maintenance Assays to measure perturbation of reservoir Latency and the extent to which it exists in different cell types Nature and origin of blips Animal models
Definitions and exclusions Each collaboration must consist of at least two interrelated research projects and involve at least two independent, faculty-level researchers. All principal and collaborating investigators must be doctoral level. Each collaboration must have access to and describe how they would use patients or clinical samples as part of their research plan. Any collaboration participant, i.e., principal or collaborating investigator, key personnel (including postdoctoral researchers and their mentors), and consultants, may be part of only one application. Special notes Please note that this RFP is differs from recent ones in the following ways: Grants will be awarded to support collaborations, not individual researchers. The direct cost maximum is $300,000. Funding may be renewable. Pre-submission forms and letters of intent are not required. Eligibility and Qualifications Collaborative research grants are awarded to nonprofit institutions worldwide to support investigator-led projects approved by the Foundation. They are not awarded to for-profit entities or to individuals. With the exception of colleges or universities, governmental units or agencies are not eligible to receive funding through grants made under this RFP. The recipient organization will be legally and financially responsible for the use of grant funds. Principal and collaborating investigators must be doctoral-level researchers and hold a faculty-level (or equivalent) position. The principal investigator must be affiliated with the applicant organization. The principal investigator will be expected to actively lead one of the component projects; actively participate in the development, implementation, and analysis of the project as whole; and be responsible for coordinating the preparation and submission of required progress reports. Collaborating investigators may be affiliated with any research organization that is not a governmental unit or agency. Collaborating investigators are expected to actively lead a component project and play an active role in the development, implementation, and analysis of the project as a whole. Forms, Instructions, and Deadlines The preferred method for obtaining application forms is to e-mail amfAR at grants@amfAR.org. We will send a complete set of forms and instructions.
Completed applications are to be e-mailed to grantapps@amfar.org no later than March 25, 5:00 p.m. EDT. Please make sure the body of the e-mail includes the principal investigator’s name and contact information. Important Notice Pre-submission notice and letters of intent are NOT required under this RFP. Applications that are received late, are incomplete, or exceed word limitations will not be accepted for review. Fax submissions are not accepted. The Research Plan consists of separate research plans of no more than 2,500 words for each of the component projects covering background and rationale, preliminary studies, specific aims, experimental design, procedures, and data analysis to be used. There are no forms for the research plan; formatting and submission requirements are detailed in the application instructions. Send one hard copy of the Collaboration Information Form (bearing original signatures) to: amfAR Grants 120 Wall Street, 13th Floor New York, NY 10005-3908, USA If you are not able to download the forms or have questions about the application requirements, please e-mail grants@amfar.org or telephone 212-806-1752. Submission of an application is not a guarantee of funding. The review and approval process is highly competitive.
Society for Hematology and Stem Cells Travel Grants to ISEH 2010 Meeting
Date: 15 - 18 September, 2010Location: Melbourne Convention & Exhibition Centre, Melbourne Australia (www.mcec.com.au/)
Through the generous support of the State government of Victoria we are able to offer up to 200 travel grants for PhD students and post-doctoral delegates as follows:Delegates traveling from Europe AUD$2000Delegates traveling from the USA AUD$1500Delegates traveling from Asia AUD$1200Delegates traveling from New Zealand or within Australia AUD$300Applications need to be submitted with your abstract and will be assessed based on the abstract rankings. Travel award applicants must also include a letter from their Mentor/Supervisor with their abstract submission requesting travel support and identifying need. *You must be an ISEH member to apply for a travel grant.
Key Dates: * Registration /Abstract Submission Open; March 1, 2010 * Abstract Submissions Close: May 1, 2010 * Travel Grant Requests Close: May 1, 2010 * Early Bird Registration Closes: June 1, 2010
The Society for Hematology and Stem Cells (ISEH) was established in 1950 by a group of scientists who sought to create a forum for the presentation and discussion of pre-clinical data in experimental hematology. ISEH continues to be dedicated to the promotion of the scientific knowledge and clinical application of basic hematologic and immunologic disorders through research, publications, and scientific programs. Incorporated in 1972 in the USA, the Society has over 800 active members from 40 countries around the world. Its annual scientific meeting attracts more than 500 participants over 4 days and, together with its official monthly journal Experimental Hematology, provides essential delivery of quality education, training programs, discussion forums, as well as promotes basic research.KnowledgeOffering comprehensive programs and publications in training and education, ISEH membership provides the tools for expansive understanding and cutting-edge methodologies from around the globe.InnovationProviding the latest scientific information, ISEH members are at the forefront of advances in experimental hematology including: * Progenitor cells, hematopoiesis, growth factors and cytokines * Immunology * Mechanisms of hematologic malignancies (leukemias, lymphomas, myelomas) * Oncology * Oncogenes * Stem Cell niches * Cancer stem cells * Gene profiling (microarray chips) and protein chips * Stem cell biology and transplantation (bone marrow, peripheral blood, cord blood) * Cellular therapy * Gene therapy * Hematopoietic microenvironment
For more information on how to apply for these grants contact ISEH@marqueemarketing.com.au
ISEH401 N. Michigan Ave, Ste 2400Chicago, IL 60611 USAPhone: (+1/202) 367-1183Fax: (+1/202) 367-2183E-mail: info@iseh.org
1
